Alzamend Neuro ALZN Cash Flow Statement (2020-2026)

NASDAQ ALZN
$1.34 +0.04 (+2.89%)
As of: Oct 21, 2026 · 10:18 AM EDT
Reported Financials

Alzamend Neuro Quarterly Cash Flow Statement

Periods 25 quarters
Latest Jul 2026

Alzamend Neuro reported cash from operations of -$1.14M and free cash flow of -$1.14M for the quarter ended Jul 2026, up 51.8% year over year. This cash flow statement covers 25 quarters of results from Jul 2020 through Jul 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jul2020 Oct2020 Jan2021 Apr2021 Jul2021 Oct2021 Jan2022 Apr2022 Jul2022 Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Jan2026 Apr2026 Jul2026
Operating Activities
Net Income
-3.60M-2.57M-3.87M-3.04M-3.11M-5.43M-3.31M-3.53M-2.91M-2.66M-0.85M-0.97M-1.42M-1.04M-1.14M-2.70M-1.00M-2.20M-2.87M-3.03M
Depreciation and DepletionDep. & Depletion
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.03M0.03M0.03M0.03M0.03M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.02M-0.02M0.01M
Depreciation & Amortization (CF)Dep. & Amort.
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.03M0.03M0.03M0.03M0.03M
Share-based CompensationStock Comp.
1.28M1.13M1.26M0.87M0.72M1.51M0.49M0.37M0.18M0.19M0.08M0.08M0.08M0.08M0.08M0.04M0.03M0.01M0.62M0.08M
Other non-cash itemsOther Non-Cash
Change in Working Capital
Change in Account PayablesChange Payables
-0.02M-0.61M0.76M-0.14M-0.38M1.99M0.23M
Change in Accured ExpensesChange Accured Exp.
-0.14M-0.38M1.99M0.23M-0.13M0.93M0.16M-0.90M-0.04M-1.63M-0.62M0.00M0.35M-0.27M1.14M-0.51M1.39M
Change in Other Operating AssetsOther Assets Change
-0.27M-0.29M-0.29M0.24M-0.42M-0.11M-0.35M0.02M-0.14M-0.27M-0.23M0.14M0.45M-0.08M-0.36M0.08M-0.04M0.71M0.07M-0.39M
Other Working Capital ChangesOther WC Changes
0.27M0.29M0.29M-0.24M0.42M0.11M0.35M-0.02M0.14M0.27M0.23M-0.14M-0.45M0.08M0.36M-0.08M0.04M-0.71M-0.07M0.39M
Cash from OperationsCash from Ops.
-2.05M-1.78M-1.56M-2.54M-2.34M-1.81M-2.24M-3.30M-1.51M-2.03M-1.43M-1.06M-3.40M-1.42M-0.69M-2.36M-1.17M-1.74M-2.80M-1.14M
Investing Activities
Capital ExpendituresCapex
0.15M0.09M0.21M
Change in Property, Plant and EquipmentChange in PP&E
-0.15M-0.09M-0.21M
Other Investing ActivitiesOther investing
Cash from Investing ActivitiesCash from Investing
-0.15M-0.09M-0.21M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Non-Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
700.00400.004.00M0.96M0.27M0.69M0.84M0.67M
Net Shares Issued and RepurchasedNet Shares Issued
700.00400.004.00M0.96M0.27M0.69M0.84M0.67M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
0.95M1.96M5.13M0.65M4.04M7.35M
Net Equity Issued and RepurchasedNet Equity Issued
700.00400.004.00M0.96M1.22M1.96M5.13M0.69M1.49M4.04M8.02M
Other financing activitiesOther financing
Cash from Financing ActivitiesCash from Financing
700.00400.003.94M2.11M1.52M1.96M6.30M0.69M1.49M4.04M0.79M8.02M
Additional items
Change in Cash
-2.05M-1.78M2.27M-2.54M-2.34M-1.81M-2.23M-3.45M-1.50M0.08M0.09M0.82M2.90M-0.73M0.59M1.67M-1.17M-1.74M-2.00M6.88M
Ending Cash Balance
11.79M14.06M11.53M9.18M7.38M5.14M1.70M0.20M0.28M0.38M1.19M4.09M3.36M3.95M5.62M4.45M2.71M0.71M7.59M
Free Cash FlowFCF
-2.05M-1.78M-1.56M-2.54M-2.34M-1.81M-2.24M-3.45M-1.51M-2.03M-1.43M-1.15M-3.40M-1.42M-0.90M-2.36M-1.17M-1.74M-2.80M-1.14M
Net Cash FlowNCF
-2.05M-1.78M2.38M-2.54M-2.34M-1.81M-2.24M-3.45M-1.51M0.08M0.09M0.82M2.90M-0.73M0.59M1.67M-1.17M-1.74M-2.00M6.88M

Alzamend Neuro Cash Flow Statement API

Pull Alzamend Neuro's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ALZN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY